Coenzyme Q10-loaded fish oil-based Bigel System: probing the delivery across porcine skin and possible interaction with fish oil fatty acids by Zulfakar, Mohd Hanif et al.
Title Page 
 
 
 
 
 
COENZYME Q10-LOADED FISH OIL-BASED BIGEL SYSTEM : PROBING THE 
DELIVERY ACROSS PORCINE SKIN AND POSSIBLE INTERACTION WITH FISH 
OIL FATTY ACIDS 
 
Mohd Hanif Zulfakar
1*
, Chan Lee Mei
1
, Khurram Rehman
1,4
, Lam Kok Wai
2
,Charles M. 
 
Heard
3
  
1
Center for Drug Delivery Research, Faculty of Pharmacy, Universiti Kebangsaan Malaysia,  
 
50300 Kuala Lumpur, Malaysia. 
 
2
Drug & Herbal Research Centre, Faculty of Pharmacy, Universiti Kebangsaan Malaysia,50300 
 
Kuala Lumpur, Malaysia. 
 
3
School of Pharmacy & Pharmaceutical Sciences, Cardiff University, King Edward VII Ave,  
 
Cardiff CF10 3NB, United Kingdom. 
 
4
Lahore Pharmacy College (A Project of Lahore Medical and Dental College), Tulspura Canal 
 
Bank, Lahore 53400, Pakistan. 
 
 
 
 
*Corresponding author 
 
Mohd Hanif Zulfakar, Ph.D. 
 
Centre for Drug Delivery Research, Faculty of Pharmacy 
 
Universiti Kebangsaan Malaysia, 
 
Jalan Raja Muda Abdul Aziz, 
 
50300, Kuala Lumpur, Malaysia 
 
Tel: +6 03 92897973 
 
Fax: +6 03 26983271 
 
Email: hanifzulfakar@ukm.edu.my 
 
 
Running head: Probing the COQ10 delivery across porcine skin 
Manuscript Body 
 
 
 
 
 
1 
 
2 Abstract 
 
3 Coenzyme Q10 (CoQ10) is a vitamin-like oil-soluble molecule that has anti-oxidant and anti- 
4 aging effects. To determine the most optimal CoQ10 delivery vehicle, CoQ10 was solubilised  
5 from fish oil and formulated into hydrogel, oleogel, and bigel. Permeability of CoQ10 from each  
6 formulation across porcine ear skin was then evaluated. Furthermore, the effects of the omega-3 
7 fatty eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids from fish oil on skin 
8 permeation were investigated by means of nuclear magnetic resonance (NMR) and computerised  
9 molecular modelling docking experiments. The highest drug permeation was achieved with the 
10 bigel formulation that proved to be the most effective vehicle in delivering CoQ10 across the  
11 skin membrane  due  to a  combination  of  its  adhesive,  viscous,  and  lipophilic properties. 
12 Furthermore, the interactions between CoQ10 and fatty acids revealed by NMR and molecular  
13 modelling experiments likely accounted for skin permeability of CoQ10. NMR data showed  
14 dose-dependent  changes  in  proton  chemical  shifts  in  EPA  and  DHA.  Molecular  modelling 
15 revealed complex formation and large binding energies between fatty acids and CoQ10. This  
16 study advances the knowledge about bigels as drug delivery vehicles and highlights the use of 
17 NMR  and  molecular  docking  studies  for  the  prediction  of  the  influence  of  drug–excipient 
18 relationships at the molecular level.  
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38 
39 Introduction 
 
40 
 
41 Coenzyme Q10 (CoQ10, ubiquinone-10), sometimes referred to as vitamin Q, is a vitamin-like 
 
42 oil-soluble molecule. It is a thermolabile lipophilic compound (logP >10) with a high molecular 
 
43 weight (863 Da) (1, 2). CoQ10 is a popular antioxidant that possesses anti-aging effects (3). 
 
44 Topical application of CoQ10 has been reported to reduce the depth of wrinkles on human skin 
 
45 (2). CoQ10 also protects skin cells from the loss of cellular activity (4). CoQ10 is a component 
 
46 of the electron transport chain in mitochondria of eukaryotic cells that plays an important role in 
 
47 generating adenosine triphosphate and inhibits cell membrane peroxidation (5). It has been also 
 
48 reported to increase the  production of basement membrane components,  thereby promoting  
 
49 fibroblast proliferation, and to protect cells against oxidative stress (2, 4). Due to its effectiveness 
 
50 after skin application, formulations of CoQ10 as a topical skin care product are now being  
 
51 considered (6). In particular, CoQ10 has been introduced into a liposomal drug delivery system 
 
52 to serve as a dermal antioxidant (2, 5). It has also been formulated into a nanoemulsion (7), a 
 
53 nanostructured lipid carrier (8), and polymer-coated liposomes for topical drug delivery (9). 
 
54 
 
55 In dermatology, topical drugs are used to treat skin diseases with the intention to distribute the 
 
56 applied active agent to the affected surrounding tissue. One of the major concerns in topical drug  
 
57 delivery is to achieve permeation of the drug in a controlled manner through the outermost part 
 
58 of the skin, the stratum corneum, to obtain the desired therapeutic effect (10). Topical and, by 
 
59 extension, transdermal delivery of drugs has many advantages as compared to other routes of 
 
60 drug administration (11, 12) because of increased patient compliance, fewer side effects, and 
 
61 immediate cessation of potential toxicity due to ease in washing off the formulation. However,  
 
62 optimal delivery may not always be successfully achieved due to the strong barrier function of 
 
63 the skin, which is attributable mostly to the highly organised structure of the stratum corneum 
 
64 (13, 14). For the purpose of drug delivery across the skin, gels are widely used as vehicles. 
 
65 
 
66 Topical gels are unique materials that are rigid and elastic in nature (15) and have a broad range 
 
67 of applications in the cosmetics, medicine, biomaterials, and food industry. Hydrogels are one of 
 
68 the  most  common  types  of  drug  delivery vehicles.  They are  three-dimensional  hydrophilic 
 
69 polymer networks able to absorb large quantities of water (16). However, when it comes to  
70 delivering the drug through stratum corneum, hydrogels lack skin permeability and are less  
 
71 compatible with lipophilic drugs (15). Gels containing oil or non-polar liquids as a dispersion 
 
72 medium are known as organogels or oleogels. Due to lipophilic compatibility with the stratum 
 
73 corneum, edible oils, such as palm oil, fish oil, and coconut oil, have been widely used to prepare 
 
74 oleogels in pharmaceutical and cosmetic products (15, 17, 18). Organogels, which are easy to 
 
75 prepare, enhance drug penetration through the stratum corneum because of their lipophilic nature 
 
76 (15, 18). Bigels, on the other hand, are colloidal mixtures of hydrogels and oleogels that possess 
 
77 the advantages of both hydrogel and oleogel systems (15, 19). Bigels have been reported to be a 
 
78 promising topical and transdermal drug delivery vehicle (19). Bigel formulations share several 
 
79 characteristics with hydrogels, namely  cooling effect, enhanced hydration of the stratum 
 
80 corneum, high spreadability, and washability by water upon application to the skin (15). The 
 
81 oleogel portion of bigels consists of fatty acids that are known to aid drug delivery across the 
 
82 skin by increasing the lipophilic nature of the formulations (19, 20). 
 
83 
 
84 Fatty acids are frequently used as penetration enhancers in formulations for transdermal and 
 
85 topical delivery of substances (21). Fish oil omega-3 fatty acids, such as eicosapentaenoic acid 
 
86 (EPA) and docosahexaenoic acid (DHA), have been demonstrated to enhance topical permeation 
 
87 of drugs (22) and have been utilised as drug delivery vehicles (19, 23, 24). These 
 
88 polyunsaturated fatty acids are thought to become incorporated within keratinocytes following  
 
89 topical application to the skin (25). Delivery of these fatty acids together with selected drugs may 
 
90 help to enhance skin permeation. In recent years, nuclear magnetic resonance (NMR) studies and  
 
91 molecular modelling have been used to investigate possible types of interactions between EPA- 
 
92 or DHA- CoQ10 complexes and their influence on CoQ10 permeation through the skin (20, 26). 
 
93 NMR spectra are highly sensitive to the local chemical environment, and NMR has been used  
 
94 previously to probe interactions, where processes such as interactions between drugs and fatty 
 
95 acids are manifested as up- or downfield shifts, depending on the magnitude of 
 
96 shielding/deshielding modulation (26, 27). 
 
97 
 
98 The aim of this study was to develop a suitable gel formulation for topical delivery of CoQ10 on 
 
99 the skin. Furthermore, the ability of delivering CoQ10 with the bigel formulation was evaluated 
 
100 in skin permeation experiments. Lastly, we investigated the interactions between fish oil fatty 
101 acids (EPA and DHA) and CoQ10 using proton NMR. Molecular models were constructed to 
 
102 predict  the  possible  geometrical  parameters  of  EPA-  or  DHA-CoQ10  complexes  and  their 
 
103 binding energies to assess the potential influence of fatty acids on CoQ10 permeation. The 
 
104 chemical structures of all the compounds included in this study are given in Fig 1. 
 
105 
 
106 
 
107 Materials and Methods 
 
108 
 
109 Materials 
 
110 
 
111 Fish  oil  from  menhaden  (crude  source  of  omega-3  fatty  acids),  cis-eicosapentaenoic  acid 
 
112 analytical  standard,  cis-docosahexaenoic  acid  analytical  standard,  cetrimide,  and  butylated 
 
113 hydroxyanisole  (BHA)  were  purchased  from  Sigma-Aldrich  (USA).  CoQ10  powder  was 
 
114 purchased from Beijing Wisapple Biotech Co., Ltd (China). Methanol and deuterated chloroform 
 
115 were purchased from Cambridge Isotope Laboratories (USA), and beeswax was obtained from 
 
116 R&M Chemicals (Selangor, Malaysia). Benzalkonium chloride and carbopol 940 were purchased  
 
117 from ACROS (New Jersey, USA), triethanolamine was obtained from Friendemann Schmidt 
 
118 (Parkwood, WA, Australia), and porcine ears were obtained from an abattoir in Ipoh, Malaysia.  
 
119 
 
120 Preparation of formulations 
 
121 
 
122 The formulations (hydrogel, oleogel, and bigel) were prepared according to the method described 
 
123 in our earlier studies (19, 20). To prepare hydrogels, ingredients (Table 1) were weighed and 
 
124 dispersed in deionised water under continuous mechanical stirring at 500 rpm (Ultraturrax ®IKA 
 
125 T25 basic, Germany) for 2 h at room temperature. Benzalkonium chloride was also added to the 
 
126 aqueous phase as a preservative and carbopol as a gelling agent. Subsequently, the mixture was  
 
127 neutralised  by adding  a  corresponding  amount  of  triethanolamine  at  a  speed  of  1000  rpm 
 
128 (Ultraturrax ®IKA T25 basic, Germany) for 15 min. 
 
129 
 
130 The oleogel was prepared by adding CoQ10, beeswax, and butylated hydroxyanisole to fish oil 
 
131 and the mixture was dissolved under continuous magnetic stirring at 300 rpm (Daihan Scientific, 
132 South Korea) at 70 °C for 15 min. CoQ10 hydrogel (CH) and CoQ10 oleogel (CO) were stored 
 
133 in an incubator at 25 °C for 24 h before being used for the preparation of bigels. After the storage 
 
134 period, bigel formulations (CB) were prepared by adding the prepared hydrogel to the oleogel at 
 
135 a 50:50 ratio (W/W) followed by homogenizing the mixture by mechanical stirring at 800 rpm.  
 
136 All prepared formulations were then stored at 5 ± 2 °C. Each formulation consisted of 5% 
 
137 CoQ10 as the  active ingredient. The  CoQ10 content was determined  by using a UV-1800 
 
138 spectrophotometer (Shimadzu, Japan) and analysed at a wavelength of λ = 275 nm. The content  
 
139 of CoQ10 in each formulation is given in Table 2. 
 
140 
 
141 
 
142 Preparation of the skin model 
 
143 
 
144 Porcine skin was used as model membrane in permeation studies due to similar thickness of its 
 
145 stratum corneum to human membrane (28, 29). Porcine ears were obtained before the carcass 
 
146 was  exposed  to  steam  cleaning  or  any  high-temperature  cleaning  procedure  to  ensure  the 
 
147 integrity of skin barrier (29). The ears were washed carefully under running water and the hair 
 
148 was shaved using an electric clipper (Aesculap, Melsungen, Germany). Precaution was taken to 
 
149 prevent any skin abrasion during shaving. The dorsal portion of the ears was removed from the  
 
150 underlying cartilage using surgical scalpel. The skin was then cut into 2×2 cm sections, and each 
 
151 skin sample was wrapped with aluminium foil to be stored at −20 °C and used within a month 
 
152 (22, 30). The dorsal portion of the skin was used for the permeation studies. 
 
153 
 
154 In vitro permeation study 
 
155 
 
156 In vitro permeation was performed using Franz diffusion cells (PermeaGear, Inc., Hellertown, 
 
157 PA, U.S.A.) with an average volume of 3.5 mL and a diffusional area of 0.95 cm
2
. Skin samples 
 
158 were mounted in Franz cells  with the stratum corneum facing the donor compartment  and 
 
159 clamped into position. Receptor chambers were filled with the receptor solution (30 mg/mL  
 
160 cetrimide and 0.05% BHA) (17, 22, 24, 25, 31) and maintained at 37 °C under continuous 
 
161 stirring at 300 rpm. The donor compartment was equilibrated with water for 1 h to facilitate skin 
 
162 hydration, which was then removed and replaced by an infinite dose (1 g) of the formulation. 
163 Samples were periodically (1, 2, 4, 6, 8, 12, and 24 h) taken from the receptor phase and 
 
164 analysed using a UV-1601 spectrophotometer at a wavelength of 275 nm (32-34). The rate of 
 
165 drug flux (mg/cm
2
/h) was obtained from the plot gradient (slope of permeation curve).  
 
166 
 
167 Skin content analysis 
 
168 
 
169 After 24 h of the experiment, the skin mounted on Franz cell was carefully removed and the  
 
170 remaining formulation that adhered to the skin surface was scraped off using a spatula. To 
 
171 determine the amount of CoQ10 retained by the skin, skin sections were soaked in methanol to 
 
172 extract CoQ10. The skin soaked in methanol was mechanically stirred overnight in a water bath 
 
173 (BW-20G,  Lab  Companion,  USA),  followed  by  ultracentrifugation  (Beckman  Coulter,  CA,  
 
174 USA) for 20 min (12,000 rpm at 10 °C) and sonication for 2 h at room temperature (20, 30). The 
 
175 resulting solutions were filtered with a 0.45 µm polytetrafluoroethylene membrane filter and the  
 
176 amount of CoQ10 was determined by using a UV-1601 spectrophotometer at a wavelength of 
 
177 275 nm and calculated against the calibration curve. 
 
178 
 
179 Nuclear magnetic resonance 
 
180 
 
181 Proton NMR studies were carried out on a Bruker Ascend
TM
  400 spectrometer. NMR was 
 
182 operating at 400 MHz and 25 °C to determine any interaction between fish oil (pure cis-EPA and 
 
183 cis-DHA) and CoQ10. Mixtures of fatty acid and CoQ10 at different ratios (75:25, 50:50, 25:75) 
 
184 were prepared using analytical grade cis-EPA and cis-DHA. Constant volumes of saturated 
 
185 solutions in deuterated chloroform (CDCl3) were added into NMR tubes. The proton NMR 
 
186 spectra were obtained and the chemical shifts were investigated. 
 
187 
 
188 
 
189 Molecular modelling 
 
190 
 
191 Computerised  molecular  modelling  of  CoQ10  and  fatty acids  (cis-EPA  and  cis-DHA)  was 
 
192 conducted to elucidate possible binding interactions between fish oil and CoQ10. The 2D and 3D 
 
193 structures of the individual drug molecules as well as of EPA and DHA fatty acid compounds  
194 were  built  with  ChemBioOffice
®
   2008  (PerkinElmer,  Inc.,  Waltham,  MA,  USA).  The  
195 minimisation using CHARM energy protocol section in Discovery Studio
®
  3.1 (Accelrys, Inc., 
 
196 San Diego, CA, USA) had been established in our laboratory (35, 36). The calculations were 
 
197 performed using 1,000 steps of the Steepest Descent with RMS gradient tolerance of 3, followed  
 
198 by  conjugate  gradient  minimisation  with  the  2000  of  maximum  number  of  cycles  for  the  
 
199 minimization and 0.1 kcal/(mol x A
o
) of minimization RMS Gradient. Docking studies were 
 
200 carried out with CDOCKER protocol section in Discovery Studio
®
  3.1. Complexes between 
 
201 CoQ10 and EPA or DHA were constructed by bringing together optimised structures and re- 
 
202 optimizing  them  using  the  same  method.  The  conformational  energy  landscape  of  these  
 
203 complexes was explored by randomly altering the mutual orientation of CoQ10 and fatty acid as  
 
204 well as the dihedral angles of any rotatable bonds. This was followed by full energy 
 
205 minimisation. During the docking process, the fatty acids as macromolecules were held rigid,  
 
206 whereas the CoQ10 was allowed to flex during the refinement. The CoQ10 was heated to 700 K 
 
207 in 2,000 steps, and the cooling temperature was set to 300 K in 5,000 steps. Grid extension was 
 
208 set automatically based on individual fatty acids. Finally, 500 random CoQ10 and EPA or DHA 
 
209 conformation poses were ranked according to their −CDOCKER interaction energy, and the 
 
210 predicted binding interactions were analysed. 
 
211 
 
212 Statistical analysis 
 
213 
 
214 Drug flux and skin content data were analysed by using one-way analysis of variance (ANOVA) 
 
215 followed by the post hoc Tukey’s multiple comparison tests. Non-parametric comparisons were 
 
216 performed by the Kruskal-Wallis test followed by the Dunn’s multiple comparison tests. All 
 
217 statistical analyses were conducted by GraphPad Prism® version 5 (GraphPad software, USA) 
 
218 with a significance level of α = 0.05 (P < 0.05). 
 
219 
 
220 
 
221 Results and discussion 
 
222 
 
223 In vitro permeation study 
 
224 
225 During in vitro permeation studies, we observed that CB formulation exhibited significantly 
 
226 higher (P < 0.05, post hoc Tukey’s test) cumulative permeation and drug flux than CO or CH 
 
227 formulations (Fig 2). CB cumulatively released 0.514 ± 0.072 mg/cm
2
, which was significantly 
 
228 higher than the amount released by CO (0.351 ± 0.034 mg/cm
2
) or CH (0.350 ± 0.04 mg/cm
2
) 
 
229 formulations. CB was also associated with a significantly higher drug flux (0.0198 ± 0.003 
 
230 mg/cm
2
/h) than that associated with CO (0.0140 ± 0.001 mg/cm
2
/h) or CH (0.0130 ± 0.001 
 
231 mg/cm
2
/h) formulations. The results are also shown in Table 2. 
 
232 
 
233 The reason for the higher CoQ10 permeation from CB formulation as compared to permeation 
 
234 from CH and CO may be in the combined effect of carbopol hydrogel and fish oil oleogel. This  
 
235 synergistic effect is likely explained by the adhesiveness of carbopol in bigels, which should  
 
236 increase the contact time with the skin, whereas the fatty acids EPA or DHA probably promote 
 
237 higher CoQ10 permeation by interrupting and disrupting the tightly packed lipids in the stratum 
 
238 corneum, leading to increased skin fluidity and, subsequently, reduced skin barrier resistance  
 
239 (19, 37). The strength of binding interactions between CoQ10 and fatty acids may correlate with 
 
240 drug flux.  To examine binding interactions between fatty acids  and CoQ10, we performed  
 
241 molecular  docking studies.  It  has  been  shown  previously that  compounds  that  have  strong 
 
242 binding interactions with fatty acids may permeate at a higher rate as a whole unit (25, 26). 
 
243 
 
244 Skin content analysis 
 
245 
 
246 Skin content analysis was performed to estimate the content of the drug retained in the skin. The  
 
247 amount of CoQ10 extracted from the skin 24 h after the exposure to each formulation is shown 
 
248 in Fig 3. The highest amount of CoQ10 was recovered from the skin that was exposed to CB 
 
249 (0.153 ± 0.027 mg), whereas amounts recovered after the use of CH (0.123 ± 0.007 mg) or CO 
 
250 (0.132 ± 0.033 mg) formulations were lower (P < 0.05, post hoc Tukey’s test). The presence of 
 
251 fish oil in oleogel (CO) and bigel (CB) formulations may have influenced the CoQ10 permeation 
 
252 by interrupting and disrupting the tightly packed lipids in stratum corneum which will lead to 
 
253 increase in skin fluidity and subsequently reduce skin barrier resistance (37). There also might be 
 
254 an influence of fish oil fatty acids (EPA and DHA) which helped CO and CB formulations to 
255 perform better in terms of CoQ10 permeation through stratum corneum and availability of drug 
 
256 inside the skin as compared to CH. 
 
257 
 
258 Nuclear magnetic resonance 
 
259 
 
260 Next, NMR experiments were conducted to analyse possible interactions between fatty acids and  
 
261 CoQ10 and their influence on each other. Mixtures of EPA-CoQ10 and DHA-CoQ10 were 
 
262 analysed in NMR and their chemical shifts were monitored. EPA-CoQ10 mixture had a dose- 
 
263 dependent  upfield  chemical  shift  at  the  region  of  2.33–2.40  ppm  of  NMR  spectra,  which 
 
264 represented the acyl groups of fatty acids (-OCO-CH2, -CH2-). This slight dose-dependent 
 
265 upfield chemical shift was in the region of carbon 20-protons of the EPA structure (Fig 4a). In 
 
266 CoQ10-DHA mixtures, there were chemical shifts of the protons in C1 and C2 of CoQ10 and in 
 
267 C1 of DHA chain. DHA-CoQ10 mixtures displayed a downfield chemical shift at the region of 
 
268 4.00–3.97  ppm  (Fig 4b)  of  spectra,  which  represented  the  -OCH3  group  of  CoQ10  in  its 
 
269 aromatic ring. It also displayed a downfield shift at 1.00–0.93 ppm (Fig 4c), which was likely 
 
270 associated with DHA acyl groups. It is clear that the addition of EPA and DHA to CoQ10 
 
271 resulted in slight chemical shifts in the signals of protons in EPA, DHA, and CoQ10 structures. 
 
272 DHA appeared to have a direct dose-dependent influence on chemical shifts of protons (-OCH3) 
 
273 of  CoQ10  located  in  the  aromatic  ring.  This  chemical  shift  pattern  may  be  due  to  weak 
 
274 interactions between protons of CoQ10 and fatty acids. Omega-3 fatty acids such as EPA and 
 
275 DHA  enhance  transport  of  drug  molecules  across  the  stratum  corneum  by  a  variety  of 
 
276 mechanisms, e.g., by increasing the lipophilic environment of the skin, partitioning into the lipid  
 
277 bilayers and disrupting their ordered domains, improving drug partitioning into the stratum 
 
278 corneum and forming lipophilic complexes with the drugs (20, 38-40). It is now well established 
 
279 that such permeation enhancers can have two possible modes of action that improve topical 
 
280 bioavailability of a drug (41). The first, known as the “push” effect, is to increase the solubility 
 
281 of the solute in the formulation and hence, its concentration gradient in solution. The second, the  
 
282 “pull” effect, is related to the flux of the enhancer itself into and through the skin, which can 
 
283 induce structural transformations of the skin barrier. This effect reduces the diffusional resistance  
 
284 of the barrier and promotes transdermal delivery of pharmacological substances. The chemical 
 
285 shifts in observed in NMR experiments correspond to these “push” and “pull” phenomena. 
 
286 
 
287 Molecular Modelling 
 
288 
 
289 To predict the influence of fatty acids and to interpret NMR results, docking experiments were  
 
290 performed  to  determine  the  relationships  between  the  fatty  acids  and  CoQ10.  Different 
 
291 geometrical models of EPA-CoQ10 and DHA-CoQ10 were assembled together to highlight the 
 
292 presence  of  any  interaction  that  could  influence  permeation.  Many  geometric  complexes  
 
293 exhibited different interactions of EPA-CoQ10 and DHA-CoQ10. It was observed that C48, C53, 
 
294 and C59 in the CoQ10 structure form weak interactions of about 3.52–4.17 Å with C20 in the 
 
295 EPA chain (Fig 5a). This -CH3---H3C interaction may be described as a hydrophobic interaction.  
 
296 There is another interaction found in the complexes of CoQ10 and EPA (Fig 5b): the aromatic 
 
297 ring of CoQ10 forms a weak π-alkyl interaction of about 4.32–4.57 Å with C20 in the EPA chain 
 
298 (aromatic ring----CH-). The protons in C1 and C2 of CoQ10 form a strong hydrogen bond with a 
 
299 carboxylic group in the EPA chain (2.40–2.96 Å). This strong interaction may be due to low 
 
300 steric hindrance of free fatty acids (42) that allow the latter to contact tighter with CoQ10 protons 
 
301 and hence, exert a greater effect. The carboxylic group in EPA has lone pairs of electrons on 
 
302 oxygen. These lone pairs of electrons contribute to the formation of another strong interaction 
 
303 (π–lone pair): between the aromatic ring of CoQ10 and a carboxylic group in EPA chain of about 
 
304 2.88 Å (Fig 5c). Weak hydrophobic interactions, weak π-alkyl interactions, hydrogen bonds and 
 
305 π-lone pair interactions between CoQ10 and EPA model predict that EPA might  influence  
 
306 CoQ10 permeation. There were also complexes between CoQ10 and DHA (Fig 6a, b). Weak 
 
307 hydrophobic interactions (-CH3---H3C) between C4, C18, C48, C58, and C59 of CoQ10 with C1 
 
308 of DHA chain (3.79–4.44 Å) were also observed. Overall, CoQ10 docked with EPA exhibited a 
 
309 favourable −CDOCKER interaction energy of 26.59 kcal/mol and CoQ10 docked with DHA had 
 
310 −CDOCKER interaction energy of 19.53 kcal/mol. These interaction energies can be considered 
 
311 as  strong  binding  energies.  According  to  CDOCKER  protocol,  the  value  of  −CDOCKER 
 
312 interaction energy is commonly reported as a positive value. The higher the value of 
 
313 −CDOCKER energy is, the stronger is receptor-ligand interaction (43). Therefore, it can be said 
 
314 that CoQ10 has a better receptor-ligand interaction with EPA than DHA. These strong binding 
 
315 energies may be due to strong hydrogen bonds and π-lone pair interactions between CoQ10 and 
 
316 fatty acids. These interactions likely contribute to the overall stability of CoQ10-fatty acids 
317 complexes and facilitate their permeation across the skin barrier as a whole unit (25). Thus, EPA 
 
318 and DHA may influence CoQ10 permeation through the skin not only by increasing its lipophilic 
 
319 environment, but also by forming lipophilic complexes with CoQ10 molecules as has been 
 
320 indicated in molecular modelling docking studies (20, 26). Due to fatty acid-CoQ10 complex 
 
321 formation, fatty acids (EPA and DHA) likely promote CoQ10 permeation through the skin via 
 
322 the “push and pull” mechanism. 
 
323 
 
324 Conclusion 
 
325 
 
326 CB formulation allowed for higher drug permeation than did CO and CH formulations. Bigel 
 
327 formulation proved to be effective in delivering CoQ10 across the skin membrane due to a 
 
328 combination of adhesiveness, viscosity, and lipophilic nature. Bigel formulation allowed a close  
 
329 contact of CoQ10 with the biological membrane and enhanced local concentration gradient, 
 
330 exhibiting properties of a superior topical drug delivery vehicle. NMR and docking experiments 
 
331 demonstrated that the omega-3 fatty acids EPA and DHA may also have positively affected 
 
332 CoQ10 permeation. NMR data demonstrated a clear pattern of chemical shifts of protons in 
 
333 CoQ10, EPA or DHA. Both EPA and DHA formed complexes with CoQ10 that improved its 
 
334 permeation through the skin via the “pull” and “push” mechanisms. The magnitude of chemical 
 
335 shifts in NMR experiments appeared to be proportional to the ratio of fatty acids (EPA and  
 
336 DHA). These results also correlated with data from docking experiments as CoQ10 expressed  
 
337 strong binding affinity towards EPA and DHA. It is possible that binding energy between fatty 
 
338 acids  and  CoQ10  influences  drug  permeation  flux.  Higher  binding  energy  and  number  of 
 
339 interactions between the CoQ10 and fatty acids may have resulted in higher drug permeation.  
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Table Caption 
 
Table 1: Composition of CoQ10 loaded hydrogels, oleogel and bigel formulations. 
 
Table 2: Content uniformity, cumulative amount of CoQ10 permeated (mg/cm
2
) and drug 
flux (mg/cm
2
/h) of CoQ10 formulations using porcine skin (Data expressed as mean ± S.D). 
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Table 1: Composition of CoQ10 loaded hydrogels, oleogel and bigel formulations 
 
 
Ingredients (g) CH (Hydrogel) CO (Oleogel)  CB (Bigel) 
 
      
 
Coenzyme Q10 5 5 CB Bigel was 
 
Carbopol 2 - prepared by 
 
Benzalkonium 0.05 - 
homogenizing 50:50  
chloride         
 
Triethanolamine 0.5 - ratio (W/W) of  CH 
 
Bees wax - 10 
and CO. 
 
 
Butylated - 0.5      
 
Hydroxianisole      
 
Deionized water 100 (q.s) -    
 
Fish oil - 100 (q.s)    
 
      
 
Table 2 
 
 
 
 
 
Table 2: Content uniformity, cumulative amount of CoQ10 permeated (mg/cm
2
) and drug flux 
(mg/cm
2
/h) of CoQ10 formulations using porcine skin (Data expressed as mean ± S.D). 
 
Formulation Content Cumulative amount of Drug flux (mg/cm
2
/h) 
 Uniformity (%) CoQ10 permeated  
  (mg/cm
2
)  
CB 99.8 0.514 ± 0.072 0.0198 ± 0.003 
CO 99.5 0.351 ± 0.034 0.0140 ± 0.001 
CH 99.2 0.350 ± 0.040 0.0130 ± 0.001 
Figure Captions 
 
 
 
 
 
Figure Caption 
 
Figure 1: Chemical structures of Coenzyme Q10, Eicosapentaenoic acid and Docosahexaenoic 
acid. 
 
Figure 2: In vitro cumulative permeation of CoQ10 loaded bigel (CB), hydrogel (CH) and 
oleogel (CO) formulation (mean ± SD, n=3, P<0.05, one-way ANOVA). 
 
 
 
Figure 3: CoQ10 extracted from porcine skin after 24 hours of permeation study (mean ± SD,  
n=3, P<0.05, one-way ANOVA). 
 
Figure 4: Fatty acids and CoQ10 mixtures showed chemical shifts in NMR spectrum of (a) 
 
EPA-CoQ10 and (b and c) DHA-CoQ10 (blue: 75%; green: 50%; red: 25% of fatty acid). 
 
 
 
 
Figure 5: (a) Molecular model of EPA and CoQ10 showing alkyl interactions, (b) possible π-
alkyl interaction and π-lone pair interactions between aromatic ring EPA-CoQ10, (c) EPA-
CoQ10 showing possible hydrogen bonds. 
 
 
 
 
Figure 6: (a-b) DHA and CoQ10 showing the possible interactions between the structure of drug 
and long of chain of fatty acid. 
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